Brain tumor is one of the most death defying diseases nowadays. The tumor contains a cluster of abnormal cells grouped around the inner portion of human brain. It affects the brain by squeezing/ damaging healthy tissues. It also amplifies intra cranial pressure and as a result tumor cells growth increases rapidly which may lead to death. It is, therefore desirable to diagnose/ detect brain tumor at an early stage that may increase the patient survival rate. The major objective of this research work is to present a new technique for the detection of tumor. The proposed architecture accurately segments and classifies the benign and malignant tumor cases. Different spatial domain methods are applied to enhance and accurately segment the input images. Moreover Alex and Google networks are utilized for classification in which two score vectors are obtained after the softmax layer. Further, both score vectors are fused and supplied to multiple classifiers along with softmax layer. Evaluation of proposed model is done on top medical image computing and computer-assisted intervention (MICCAI) challenge datasets i.e., multimodal brain tumor segmentation (BRATS) 2013, 2014, 2015, 2016 and ischemic stroke lesion segmentation (ISLES) 2018 respectively.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10916-019-1453-8DOI Listing

Publication Analysis

Top Keywords

brain tumor
16
tumor
8
tumor segmentation
8
score vectors
8
softmax layer
8
brain
5
approach brain
4
segmentation classification
4
classification based
4
based score
4

Similar Publications

Introduction: Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with disease progression on/after osimertinib and platinum-based chemotherapy are limited.

Methods: CHRYSALIS-2 Cohort A evaluated amivantamab+lazertinib in patients with EGFR exon 19 deletion- or L858R-mutated NSCLC with disease progression on/after osimertinib and platinum-based chemotherapy. Primary endpoint was investigator-assessed objective response rate (ORR).

View Article and Find Full Text PDF

Evaluating the impact of performance status in elderly patients with glioblastoma.

J Clin Neurosci

January 2025

Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; Department of Neurosurgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA. Electronic address:

Background: Glioblastoma (GBM) is a common brain tumor with a poor prognosis. There is a paucity of knowledge regarding optimal treatment approaches for elderly patients with GBM who have a relatively good Karnofsky (KPS) or Eastern Cooperative Oncology Group (ECOG) performance status. This study compared treatment outcomes in older patients (≥65) with GBM based on their performance status, either high (KPS ≥ 70 and ECOG < 2) or low (KPS < 70 and ECOG ≥ 2), who underwent hypofractionated radiotherapy (HFRT) (40 Gy in 15 fractions) versus conventional fractionation (60 Gy in 30 fractions).

View Article and Find Full Text PDF

Background: Brain metastases (BMs) are common in human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer, increasing morbidity and mortality. Systemic therapy for BMs can be effective, with the triple combination of trastuzumab, capecitabine, and tucatinib being a potential standard. More recently, intracranial activity of antibody-drug conjugates has been reported, but the size of individual studies has been small.

View Article and Find Full Text PDF

Hierarchically Engineered Self-Adaptive Nanoplatform Guided Intuitive and Precision Interventions for Deep-Seated Glioblastoma.

ACS Nano

January 2025

Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.

Glioblastoma multiforme (GBM), particularly the deep-seated tumor where surgical removal is not feasible, poses great challenges for clinical treatments due to complicated biological barriers and the risk of damaging healthy brain tissue. Here, we hierarchically engineer a self-adaptive nanoplatform (SAN) that overcomes delivery barriers by dynamically adjusting its structure, surface charge, particle size, and targeting moieties to precisely distinguish between tumor and parenchyma cells. We further devise a AN-uided ntuitive and recision ntervention (SGIPi) strategy which obviates the need for sophisticated facilities, skilled operations, and real-time magnetic resonance imaging (MRI) guidance required by current MRI-guided laser or ultrasound interventions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!